Navigation Links
Novavax Announces Closing of $18 Million Registered Direct Offering
Date:8/1/2008

inant proteins.

Novavax's VLPs resemble a virus but lack the genetic material that would cause infection. Using the Company's proprietary VLP technologies, Novavax is developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other viral diseases. The Company also utilizes a unique portable manufacturing system that allows for rapid production of vaccines requiring less infrastructure and represents a potential simpler and more efficient approach to vaccine production. Additional information about Novavax is available at http://www.novavax.com and in the Company's various filings with the SEC.

Forward Looking Statements Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding revenues, operating expenses, cash burn, and clinical developments and anticipated milestones are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the Company's ability to progress any product candidates in preclinical or clinical trials; the scope, rate and progress of its preclinical studies and clinical trials and other research and development activities; the results of clinical trials; even if the data from preclinical studies or clinical trials is positive, the product may not prove to be safe and efficacious; Novavax's pilot plant facility is subject to extensive validation and FDA inspections, which may result in delays and increased costs; the effect or outcome of the Company's decision to sell Estrasorb(R); the human c
'/>"/>

SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Novavax CEO to Present at BIO CEO & Investor Conference
2. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
3. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
4. Novavax CEO to Present at the World Vaccine Congress 2008
5. Novavax Opens Its First U.S. Vaccine Plant
6. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
7. Novavax Reports First Quarter 2008 Financial Results
8. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
9. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
10. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
11. Novavax to Join Russell 3000 Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014   BioLife Solutions , Inc. (NASDAQ: BLFS ... grade hypothermic storage and cryopreservation freeze ... and tissues  ("BioLife" or the "Company"), today announced that it ... 4, 2015 (the "Annual Meeting"). Because the expected ...
(Date:12/24/2014)... 23, 2014 Earlier this year in a ... of the Adult Stem Cell Technology Center, LLC ( ASCTC ... unique property of adult tissue stem cells. His title ... Important for the Future,” embodied the essence of his message ...
(Date:12/24/2014)... According to Ross Selinger, President of Selinger ... the national office market continues to be strong, driven by ... by the third quarter’s surprising 3.9% GDP, unemployment decreasing to ... have held inflation down and the Fed is keeping interest ...
(Date:12/24/2014)... 2014 The report expects global cell isolation ... also provides a carefully analyzed data about the vital drivers, ... Full Copy of Report @ http://bit.ly/1yUxy0T , According ... keep witnessing growth at an impressive CAGR during near future. ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3
... conjunction with,CorVel Corporation,s (Nasdaq: CRVL ) fiscal year earnings release, CorVel,will be ... June 10th at 11:30 am Eastern Time., Event: ... Starck, President and CEO ... 11:30 am Eastern Time, Tuesday, June 10th, 2008, Login: ...
... Xceed,s Dr. David Englert and Dr. Zhe Zhang of Children,s Hospital of, ... ... 21st, WELLESLEY, ... easy-to-use gene-expression analysis,systems, announced that the company will feature its Ziplex Automated,Gene-Expression ...
... China, May 16 /Xinhua-PRNewswire-FirstCall/ --,China Pharma Holdings, ... develops, manufactures, and markets generic and brand,bio-pharmaceutical ... donated 2,million RMB (approximately US$285,714) worth of ... medicines to help disaster relief in,China after ...
Cached Biology Technology:CorVel Corporation Announces Earnings Release Webcast 2Xceed Molecular Features Ziplex(R) Automated Gene-Expression System at the Biomarker World Congress, Booth 16 2China Pharma Holdings, Inc. Donates Medicine for Sichuan Earthquake Relief 2
(Date:12/17/2014)... 2014  HITLAB SM announced today its completion of ... adherence to current U.S. Food and Drug Administration (FDA) ... device and smart phone application trials utilizing the highest ... "HITLAB is determined to improve global healthcare access, quality, ...
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) has ... Market 2015-2019" report to their offering. ... is a technology used for the identification of individuals. ... a person such as nose, jaw edges, mouth, and ...
(Date:12/11/2014)... 10, 2014  Data Sciences International (DSI), the global ... new series of digital telemetry implants to meet ... series, part of the PhysioTel™ Digital platform, was ... physiologic data when incorporating functional endpoints into repeat-dose ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2
... Italian research team, publishing in the current issue of ... on-line without charge at http://www.ingentaconnect.com/content/cog/ct , has found ... play a role in the treatment of lung diseases, ... tuberculosis, chemical exposure, radiation or pathogens. These diseases can ...
... Muscular Atrophy is the second-leading cause of infant mortality in ... at Iowa State University,s College of Veterinary Medicine, would like ... even slide off the list altogether. , Most Spinal Muscular ... mutated or deleted gene called Survival Motor Neuron 1 (SMN1) ...
... at Penn State University, in collaboration with institutes in the ... long-sought structure of a layer of C60 carbon buckyballs ... help in the design of carbon nanostructure-based electronics are reported ... July 27th issue of APS,s on-line journal Physics ...
Cached Biology News:Placenta-derived stem cells may help sufferers of lung diseases 2ISU researchers find possible treatment for spinal muscular atrophy 2
... Service, We deliversoluble protein or No ... yields the best soluble protein results , ... clone submitted , Powerful results on your ... Solubility Optimization Service (SOS) uses proprietary tools ...
... cDNA Library Panels were designed for full-length ... of PCRs to identify the desired cDNA ... in a 96-well "Master Plate," where each ... Having identified the positive well(s) by gel ...
... ProteinChip beta-amyloid Multipeptide Kit, designed for ... detecting a variety of amyloid peptides ... before. - Clinical neuroscience proteomics applications ... treatment - Correlate beta-amyloid peptide levels ...
Formula variant: With the macro- and micronutrients as described by Lloyd and McCown (1981). Preparation Quantity Equivalency: Formulated to contain 2.3 grams of powder per liter of medium. Physical ...
Biology Products: